{"groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"FG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Study Terminated By Sponsor"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"4"}],"type":"Death"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"10"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 10 participants were screened and enrolled in the study.","recruitmentDetails":"The study was conducted at 2 different sites in USA. A total of 10 participants were enrolled in the study."}